Is the CSL share price heading back over $300 in 2022?

Is 2022 CSL's year of $300 a share?

| More on:
A doctor looks unsure, indicating share price uncertainty for ASX medical companies

Image source: Getty images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The CSL share price has been stuck on struggle street for a while now
  • The company has been treading water for some years and hasn't seen $300 a share so far in 2022
  • But could this be the year where CSL shares resume their growth?

The CSL Limited (ASX: CSL) share price has been somewhat of a lacklustre performer of late, especially when compared to its stellar runs of a few years ago. At the time of writing, CSL shares are going for $269.12 each, up a healthy 2.03% so far today.

However, CSL first crossed this pricing threshold back in November 2019. That means this ASX 200 healthcare giant has essentially been treading water ever since. That's 2-and-a-half years of waiting that shareholders have had to endure, with only CSL's sub-1% dividend yield for company.

That contrasts painfully with prior years when CSL shareholders enjoyed double-digit share price growth over 2017, 2018, and 2019.

Not that the recent share price woes are entirely CSL's fault. It was trading at what was arguably quite a high price-to-earnings (P/E) ratio prior to the COVID-induced crash of 2020. Even today, it commands a solid P/E ratio of more than 36. And the pandemic has hit CSL hard, disrupting its plasma collection businesses around the world.

What's notable is that CSL has been markedly higher in the past. The company hit more than $336 a share back in early 2020, its current all-time high. And the company's present 52-week high is at $319.78.

Is 2022 the CSL share price's $300 year?

So is 2022 the year that CSL crosses the Rubicon and heads back to a share price north of $300?

Well, one broker who thinks it might be CSL's $300 year is Citi. As we covered yesterday, Citi has just retained its buy rating on CSL shares, replete with a 12-month share price target of $335. That would imply a potential upside of almost 25% on today's pricing.

Citi reckons CSL's plasma collections will come roaring back this year, exceeding pre-pandemic levels. This, the broker expects, will result in a "big boost to investor sentiment".

No doubt shareholders who have been waiting since November 2019 for the CSL share price to keep climbing will be hoping Citi's predictions are spot on. But we shall have to wait and see, as always.

At the current CSL share price, this ASX 200 healthcare giant has a market capitalisation of $129.6 billion, with a mostly unfranked dividend yield of 0.96%

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A young office worker is surrounded by peers who are clapping and congratulating her.
Healthcare Shares

Up 140% in 2024, here's why this ASX 200 healthcare stock is making news again today

It’s yet another positive update for this stock.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 ASX healthcare shares surging on big news

The ASX healthcare sector is higher on Tuesday and these stocks are among the strongest performers.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

The pros and cons of buying CSL shares right now

It’s an interesting time to consider this healthcare giant.

Read more »

Vanadium Resources share price person riding rocket indicating share price increase
Healthcare Shares

Why did this ASX biotech stock explode 52% higher on Monday?

Shareholders of this stock were smiling today. What happened?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is everyone talking about ResMed shares?

It’s been a good year for ResMed shareholders. Let’s find out why.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »